Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Down 82.5% in May

Fresenius SE & Co. (OTCMKTS:FSNUY) saw a significant decrease in short interest in the month of May. As of May 29th, there was short interest totaling 8,663 shares, a decrease of 82.5% from the May 14th total of 49,381 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 403,780 shares, the short-interest ratio is currently 0.0 days.

Fresenius SE & Co. Price Performance

Shares of OTCMKTS FSNUY remained flat at $10.93 during mid-day trading on Thursday. 249,560 shares of the stock were exchanged, compared to its average volume of 117,829. The company has a market capitalization of $24.62 billion, a PE ratio of 14.57 and a beta of 0.64. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.98 and a current ratio of 1.27. Fresenius SE & Co. has a 52-week low of $10.33 and a 52-week high of $33.93. The business has a fifty day moving average of $11.90 and a 200-day moving average of $13.36.

Fresenius SE & Co. (OTCMKTS:FSNUY) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). The company had revenue of $6.75 billion during the quarter, compared to analysts’ expectations of $6.79 billion. Fresenius SE & Co. had a return on equity of 10.09% and a net margin of 6.55%. Equities research analysts anticipate that Fresenius SE & Co. will post 1.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, Morgan Stanley reissued an “overweight” rating on shares of Fresenius SE & Co. in a research report on Monday, April 20th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Fresenius SE & Co. currently has a consensus rating of “Buy”.

Fresenius SE & Co. Company Profile

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.